12:00 AM
 | 
Dec 17, 2007
 |  BioCentury  |  Regulation

Pulzium cardiac adverse events

Pulzium cardiac adverse events

Pulzium cardiac adverse events
Cardiac adverse events in many cases were higher among patients who received Pulzium tedisamil than in the placebo arm and increased with dose. Selected treatment emergent cardiac adverse events are listed below. Source: Solvay briefing documents
0.24 mg/kg 0.32 mg/kg

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >